IRBM and Merck extend peptide therapeutics collaboration

Peptide

Italian contract research organisation IRBM has signed a new agreement with Merck & Co Inc (MSD outside the USA and Canada) to continue their collaboration in the peptide therapeutics area.

“The success of this collaboration is reflected by the outstanding achievements in the delivery of orally available peptide candidates,” said Elisabetta Bianchi, Senior Director of Peptide Chemistry at IRBM. “We are thrilled to continue this collaboration as part of our mission to advance impactful agents into the clinic.”

In recent years, significant advances have been made in peptide discovery through the well-established phage and mRNA display platforms and with major progress achieved for half-life extension strategies and the use of formulation enhancers to support oral route administration.

The collaboration has taken advantage of these novel technologies to develop peptide candidates that progress into the clinic.

“At MSD, we continue to evaluate the opportunities for peptide-based therapeutic candidates across multiple indications,” said Rob Garbaccio, Vice President, Head of Discovery Chemistry at MSD Research Laboratories. “We look forward to continuing our productive collaboration with our colleagues at IRBM in this compelling area of research.”

The delivery of candidate peptide drugs is supported by the use of phage display peptide libraries for hit identification, synthetic strategies from macrocycles to proteins, molecular design and engineering, structural biology, biochemical, biophysical and cell-based assay to enable structural activity relationship studies as well as in vitro and in vivo ADME studies.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free